AVBP ArriVent BioPharma, Inc.

$29.51

ArriVent BioPharma, Inc. (AVBP) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is a loss of $1.04 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.0% since its last earnings release on August 12, 2026.

ArriVent BioPharma Missed Consensus Estimates
Wednesday, August 12, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 11
Wednesday · 4:00 PM ET
Earnings Whisper
-
vs ($1.04)
Rev est $71.27M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $29.77

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About ArriVent BioPharma, Inc.

ArriVent BioPharma Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent BioPharma Inc. is based in NEWTOWN SQUARE, Pa.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow